<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="221302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202592</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-90652-002</org_study_id>
    <nct_id>NCT00202592</nct_id>
  </id_info>
  <brief_title>S90652 in Paediatric Hypertension</brief_title>
  <official_title>Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children - 24 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the long-term safety and effects on blood pressure of a
      paediatric formulation of perindopril in hypertensive children
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical safety assessed from the patient's (parents) complaints and clinical follow-up</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive children, who have been treated for four months at least with S90652,
             with safety and efficacy

        Exclusion Criteria:

          -  Poorly controlled hypertension

          -  Girls with signs of pubescence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Niaudet, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Necker-Enfants Malades, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 15, 2011</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
